Introduction {#s1}
============

Efficacious biomedical HIV prevention interventions could dramatically reduce the number of new HIV infections globally [@pone.0060024-Cohen1]--[@pone.0060024-McGowan1]. Microbicides (also referred to as topical pre-exposure prophylaxis \[topical PrEP\]) represent one of several classes (e.g. oral PrEP, treatment-as-prevention) of such interventions currently being developed [@pone.0060024-AbdoolKarim1]--[@pone.0060024-VanDamme1]. There are multiple reasons why microbicides are attractive as tools for HIV prevention: (i) local administration of an antiretroviral gel at the site of exposure will result in higher drug levels at the intended anatomical location than can be achieved using oral PrEP [@pone.0060024-Hendrix1]--[@pone.0060024-Anton2] while reducing the likelihood of experiencing systemic dosing-associated toxicities [@pone.0060024-Thigpen1], [@pone.0060024-Anton2]; (ii) the reduced toxicity associated with topical microbicides is expected to increase adherence [@pone.0060024-McGowan2]; (iii) microbicides are user controlled [@pone.0060024-Shattock1]; (iv) microbicides are predicted to be cost-effective [@pone.0060024-Walensky1], [@pone.0060024-Williams1]; (v) topical microbicides can be developed with combinations of viral inhibitors [@pone.0060024-McGowan3]; (vi) an ideal microbicide would be safe and effective in both rectal and vaginal compartments [@pone.0060024-Balzarini1]--[@pone.0060024-Dezzutti2]; and (vii) antiviral microbicides may also protect against viruses other than HIV (e.g. herpes simplex) [@pone.0060024-AbdoolKarim2], [@pone.0060024-Tan1].

All microbicide efficacy clinical trials to date have tested the prevention of vaginal HIV transmission [@pone.0060024-Cutler1], [@pone.0060024-AbdoolKarim1], [@pone.0060024-McGowan2], [@pone.0060024-Peterson1]--[@pone.0060024-VanDamme3]. However, an important driver of the epidemic in both men and women is HIV transmission resulting from anal intercourse [@pone.0060024-Jansen1]--[@pone.0060024-Hendrix2] such that rectal microbicide development is also required [@pone.0060024-McGowan2], [@pone.0060024-Abner1]--[@pone.0060024-Sudol1]. Proof of concept that administration of an antiretroviral gel rectally can prevent transmission of SIV/SHIV has been demonstrated for tenofovir [@pone.0060024-Cranage1] and MIV-150 [@pone.0060024-Singer1]. Tenofovir, UC781, and nonoxynol-9 have been tested for safety and acceptability in Phase 1 rectal microbicide clinical trials and, of these three, only tenofovir is being advanced [@pone.0060024-Anton1]--[@pone.0060024-McGowan2], [@pone.0060024-Tabet1], [@pone.0060024-McGowan4]. Therefore, our *in vivo* preclinical efficacy study in bone marrow-liver-thymus (BLT) humanized mice was designed to determine the efficacy of topical tenofovir for the prevention of rectal HIV-1 transmission.

BLT mice are the experimental platform of choice for this study for several reasons. For example, BLT mice harbor a *de novo* generated human immune system distributed throughout each animal [@pone.0060024-Denton1]--[@pone.0060024-Chateau1]. In the context of this study, an important characteristic of BLT mice is their susceptibility to rectal HIV-1 transmission [@pone.0060024-Denton5], [@pone.0060024-Sun1] due to the presence of human CD4^+^ T cells, macrophages and dendritic cells found throughout BLT mouse intestines, including the rectum [@pone.0060024-Denton1], [@pone.0060024-Sun1]. Previously both topical [@pone.0060024-Denton3] and systemic [@pone.0060024-Denton4], [@pone.0060024-Denton5] HIV prevention interventions have been extensively tested in BLT mice for their ability to block vaginal transmission of HIV-1. The results obtained from these studies were highly predictive of the clinical trial outcomes [@pone.0060024-AbdoolKarim1], [@pone.0060024-Grant1], [@pone.0060024-Denton3], [@pone.0060024-Denton4], [@pone.0060024-Denton5], [@pone.0060024-Denton6].

An important and novel aspect of this study is the use of a MSM-derived transmitted/founder (T/F) virus [@pone.0060024-Ochsenbauer1]. Typically only one or a few virions (defined as the T/F viruses) are responsible for a mucosal transmission event in humans making T/F viruses physiological relevant for *in vivo* efficacy studies of HIV prevention interventions [@pone.0060024-Keele1], [@pone.0060024-SalazarGonzalez1]. BLT mice were treated rectally with topical 1% tenofovir and then rectally inoculated with HIV-1~JRCSF~, a well characterized low passage primary isolate, or the T/F virus HIV-1~THRO~. We found that rectal transmission of both viruses was efficiently prevented by topical tenofovir.

Materials and Methods {#s2}
=====================

Preparation of BLT Mice and Characterization of Human Reconstitution {#s2a}
--------------------------------------------------------------------

BLT mice were prepared essentially as previously described [@pone.0060024-Denton1]--[@pone.0060024-Melkus1], [@pone.0060024-Sun1], [@pone.0060024-Chateau1]. Briefly, thy/liv implanted [@pone.0060024-McCune1] and preconditioned NOD/SCID-gamma chain null (NSG) mice (Jackson Laboratories, Bar Harbor, ME) were transplanted with autologous human fetal liver CD34^+^ cells (Advanced Bioscience Resources, Alameda, CA) and monitored for human reconstitution in peripheral blood by flow cytometry [@pone.0060024-Denton4], [@pone.0060024-Melkus1], [@pone.0060024-Sun1]. Mice were maintained at the University of North Carolina at Chapel Hill Division of Laboratory Animal Medicine in accordance with protocols approved by the Institutional Animal Care and Use Committee.

Topical Application of Tenofovir and Rectal Exposure of BLT Mice to HIV-1 {#s2b}
-------------------------------------------------------------------------

Stocks of HIV-1~JRCSF~ [@pone.0060024-Koyanagi1] and HIV-1~THRO~ [@pone.0060024-Ochsenbauer1] were prepared and titered as we have previously described [@pone.0060024-Wahl1], [@pone.0060024-Wei1]. Mice were exposed rectally using 0.6 µg p24 of HIV-1~JRCSF~ (4×10^6^ TCIU, tissue culture infectious units) and 0.7 µg p24 of HIV-1~THRO~ (5×10^6^ TCIU). Topical tenofovir consisted of 1% tenofovir (PMPA; 9-(2-phosphonyl-methoxypropyly)-adenine) in PBS. The vehicle (placebo) control was PBS.

The exposure timeline ([Figure 1](#pone-0060024-g001){ref-type="fig"}) consisted of rectal application of vehicle or of 1% tenofovir less than 30 minutes prior to rectal application of virus. Rectal exposures with HIV-1~JRCSF~ and HIV-1~THRO~ were performed essentially as previously described [@pone.0060024-Denton5], [@pone.0060024-Sun1] except that all the mucosal exposures were carried out atraumatically and without simulated rectal intercourse [@pone.0060024-Berges1]. All rectal applications of vehicle or inhibitor as well as virus were performed while mice were anesthetized [@pone.0060024-Denton5], [@pone.0060024-Sun1]. After viral exposure, mice were returned to their housing to recover and were then monitored longitudinally for evidence of HIV-1 infection as indicated below.

![Experimental design and timeline.\
BLT mice were utilized to determine the efficacy of topically applied tenofovir to prevent rectal HIV-1 transmission. Rectal HIV-1 exposures were performed within 30 minutes following rectal application of 1% tenofovir. Plasma viral load and real time PCR amplification of tissue associated viral DNA were used as HIV-1 detection strategies to determine whether peripheral blood samples collected at the indicated times and tissues collected at harvest contained HIV-1.](pone.0060024.g001){#pone-0060024-g001}

Analysis of HIV-1 Infection of BLT Mice {#s2c}
---------------------------------------

Infection of BLT mice with HIV-1 was monitored at the indicated time intervals in peripheral blood by determining plasma levels of viral RNA using real time PCR (limit of detection 750 copies/ml) [@pone.0060024-Denton2], [@pone.0060024-Denton3] and by monitoring CD4^+^ T cell percentages by flow cytometry [@pone.0060024-Denton4], [@pone.0060024-Denton5]. At necropsy, tissues were harvested and mononuclear cells isolated as previously described [@pone.0060024-Denton1], [@pone.0060024-Denton3], [@pone.0060024-Denton4], [@pone.0060024-Melkus1], [@pone.0060024-Sun1]. Mononuclear cells were washed, enumerated and tested using real time PCR for the presence of HIV-1 DNA (limit of detection 10 copies) [@pone.0060024-Denton3], [@pone.0060024-Wahl1], [@pone.0060024-Denton4], [@pone.0060024-Denton5].

Sequence analysis was performed on plasma RNA samples in the sole case of breakthrough infection of a tenofovir-treated, HIV-1~JRCSF~-exposed BLT mouse. The entire reverse transcriptase gene from plasma HIV-1 RNA amplification products was sequenced. No resistance mutations in reverse transcriptase were present [@pone.0060024-Gu1]--[@pone.0060024-White1].

Statistics {#s2d}
----------

All statistical analyses (alpha level: 0.05) were performed using Prism v. 5 (Graph Pad Software). Kaplan-Meier plots indicate the percentage of animals that are HIV-1 positive in the peripheral blood at each time point analyzed. Power analysis calculation for experimental group sample sizes were determined as previously described [@pone.0060024-Hudgens1], [@pone.0060024-Hudgens2]. Briefly, we assumed 50 and 65% variance in transmission between our experimental groups for HIV-1~JRCSF~ and HIV-1~THRO~, respectively. In the case of each viral isolate, the chosen sample sizes were determined to have 90% power to detect statistically significant differences via log rank test analysis in the treatment arm versus the vehicle arm.

Results {#s3}
=======

Baseline Characterization of BLT Mouse Human PBMC Reconstitution {#s3a}
----------------------------------------------------------------

This study was designed to determine the *in vivo* efficacy of topical tenofovir for the prevention of rectal HIV-1 transmission. Prior to HIV-1 exposure of the BLT mice, their peripheral blood was characterized by flow cytometry to confirm reconstitution with human cells. All BLT mice used herein (n = 43) had high peripheral blood reconstitution levels of human lymphoid (CD45^+^) cells (67% mean ±17 SD) and human CD4^+^ T cells (80% mean ±6 SD) (Summarized in [Tables 1](#pone-0060024-t001){ref-type="table"} and [2](#pone-0060024-t002){ref-type="table"}).

10.1371/journal.pone.0060024.t001

###### BLT mice used to test the efficacy of topical tenofovir to prevent rectal **HIV-1~JRCSF~** transmission.[\*](#nt101){ref-type="table-fn"}

![](pone.0060024.t001){#pone-0060024-t001-1}

                              Mouse      \% human CD45^+^ in PBat exposure   \% hCD45^+^ hCD3^+^ hCD4^+^in PB at exposure   Tissue Cell associatedviral DNA^∧^   HIV Status
  ----------------------- ------------- ----------------------------------- ---------------------------------------------- ------------------------------------ ------------
  **Topical Tenofovir**        J01                      78                                        87                                   B, S, O, LN                  Neg
                               J02                      69                                        86                                   B, S, O, LN,                 Neg
                               J03                      67                                        79                                   B, S, O, LN                  Neg
                               J04                      39                                        83                                   B, S, O, LN                  Neg
                               J05                      78                                        67                               **B,** S, **O, LN**            **Pos**
                               J06                      54                                        84                                     B, O, LN                   Neg
                               J07                      69                                        71                                     B, S, LN                   Neg
                               J08                      73                                        68                                   BM, S, O, LN                 Neg
                               J09                      86                                        69                                        ND                      Neg
                               J10                      65                                        88                                   BM, S, O, LN                 Neg
                               J11                      79                                        86                                     B, S, O                    Neg
                               J12                      80                                        86                                   BM, S, O, LN                 Neg
  Mean (+/− SD)            70% (+/−13)              80% (+/−8)                                                                                                  
  **Vehicle**                  J13                      73                                        88                                 **B, S, O, LN**              **Pos**
                               J14                      52                                        79                                        ND                      Neg
                               J15                      32                                        85                                        ND                      Neg
                               J16                      84                                        73                               **B,** S, **O,** LN,           **Pos**
                               J17                      68                                        86                                        ND                    **Pos**
                               J18                      56                                        85                                        ND                      Neg
                               J19                      31                                        79                                       B, S                   **Pos**
                               J20                      83                                        72                                     B, O, S,                   Neg
                               J21                      61                                        71                                  **S, O, LN,**               **Pos**
                               J22                      71                                        83                                        ND                      Neg
                               J23                      79                                        88                                   B, S, O, LN                  Neg
                               J24                      62                                        84                                   B, S, O, LN                  Neg
                               J25                      72                                        84                                        ND                      Neg
                               J26                      60                                        80                                   **S, O, LN**               **Pos**
                               J27                      75                                        82                                   B, S, O, LN                  Neg
                               J28                      76                                        88                                 **B, S, O, LN**              **Pos**
                               J29                      77                                        87                                        ND                    **Pos**
  Mean (+/− SD)            65% (+/−16)              82% (+/−6)                                                                                                  

The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold used to highlight that HIV-1 was found in the indicated tissues.

ˆAbbreviations: B -- bone marrow; LN --lymph nodes; ND - not done; Neg -- negative; O -- thymic organoid; PB -- peripheral blood; Pos -- positive; and S -- spleen.

10.1371/journal.pone.0060024.t002

###### BLT mice used to test the efficacy of topical tenofovir to prevent rectal **HIV-1~THRO~** transmission.[\*](#nt103){ref-type="table-fn"}.

![](pone.0060024.t002){#pone-0060024-t002-2}

                              Mouse      \% human CD45+in PB at exposure   \% hCD45+ hCD3+ hCD4+in PB at exposure   Tissue Cell associatedviral DNA^∧^   HIV Status
  ----------------------- ------------- --------------------------------- ---------------------------------------- ------------------------------------ ------------
  **Topical Tenofovir**        T01                     56                                    83                                B, S, O, LN                  Neg
                               T02                     81                                    81                                B, S, O, LN                  Neg
                               T03                     82                                    77                                B, S, O, LN                  Neg
                               T04                     87                                    82                                B, S, O, LN                  Neg
                               T05                     24                                    80                                B, S, O, LN                  Neg
                               T06                     29                                    80                                B, S, O, LN                  Neg
  Mean (+/− SD)            60% (+/−28)             81% (+/−2)                                                                                           
  **Vehicle**                  T07                     61                                    82                                **B, S, O,**               **Pos**
                               T08                     85                                    81                                B, S, O, LN                  Neg
                               T09                     70                                    76                                **B, S, O**                **Pos**
                               T10                     86                                    78                                **B, S, O**                **Pos**
                               T11                     42                                    83                                **B, S, O**                **Pos**
                               T12                     56                                    77                                     ND                      Neg
                               T13                     83                                    75                                 B, S, O,LN                  Neg
                               T14                     73                                    78                                     ND                    **Pos**
  Mean (+/− SD)            70% (+/−16)             79% (+/−3)                                                                                           

The data shown in the table includes analyses performed on both infected and uninfected mice with the text in bold used to highlight that HIV-1 was found in the indicated tissues.

ˆAbbreviations: B -- bone marrow; LN --lymph nodes; ND - not done; Neg -- negative; O -- thymic organoid; PB -- peripheral blood; Pos -- positive; and S -- spleen.

Topical Tenofovir Prevents Rectal HIV-1~JRCSF~ Transmission {#s3b}
-----------------------------------------------------------

A total of 29 mice were exposed to HIV-1~JRCSF~, a CCR5-tropic virus that has been well characterized for its mucosal infection of BLT mice [@pone.0060024-Denton3], [@pone.0060024-Wahl1], [@pone.0060024-Denton4], [@pone.0060024-Denton5], [@pone.0060024-Sun1], [@pone.0060024-Wheeler1], [@pone.0060024-Chateau1]. Seventeen mice received vehicle and 12 mice received topical tenofovir ([Figure 2](#pone-0060024-g002){ref-type="fig"}; [Table 1](#pone-0060024-t001){ref-type="table"}). Following viral exposure, peripheral blood from the BLT mice was sampled weekly for the presence of HIV-1 RNA ([Figure 1](#pone-0060024-g001){ref-type="fig"}). Eight of the 17 mice in the control arm of the experiment were infected as determined by the presence of viral RNA in plasma ([Figure 2A](#pone-0060024-g002){ref-type="fig"}). In contrast, 11 of 12 topical tenofovir treated mice were consistently negative for the presence of plasma viral RNA ([Figure 2A](#pone-0060024-g002){ref-type="fig"}). One tenofovir treated mouse was found to have a 'breakthrough' infection with readily detectable plasma viral RNA ([Figure 2A](#pone-0060024-g002){ref-type="fig"}). No tenofovir resistant mutations from this breakthrough virus were identified when the entire reverse transcriptase gene was sequenced. Over the course of this experiment, we also monitored the levels of CD4^+^ T cells in peripheral blood. The breakthrough infection mouse and the infected vehicle control mice maintained similar peripheral blood CD4^+^ T cell levels to the HIV-1 negative mice ([Figure 2B](#pone-0060024-g002){ref-type="fig"}), as we have previously observed with this CCR5-tropic HIV-1 isolate in BLT mice [@pone.0060024-Denton4], [@pone.0060024-Denton5].

![Analysis of peripheral blood and tissues for the presence of HIV-1~JRCSF~ after rectal exposure in the presence or absence of topical tenofovir.\
(A--B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the percentage of peripheral blood CD3^+^ T cells also expressing CD4 (B) are presented for vehicle (left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1~JRCSF~. (C) Real-time PCR analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent the limit of detection for the respective assays. Error bars indicate standard error of the mean. Open symbols are used to depict data from HIV negative mice and closed symbols are used to depict data from HIV positive mice.](pone.0060024.g002){#pone-0060024-g002}

Prior to defining topical tenofovir treated BLT mice as protected from rectal HIV-1 transmission, we tested tissues harvested from these mice for the presence of cell-associated HIV-1 DNA. All mice without plasma viral RNA were also found to be negative for viral DNA in all tissues evaluated (e.g. bone marrow, spleen, human thymic organoid and lymph nodes) confirming the lack of HIV-1 transmission in these animals ([Figure 2C](#pone-0060024-g002){ref-type="fig"}; [Table 1](#pone-0060024-t001){ref-type="table"}). The HIV status and time to plasma viremia were then combined to generate a Kaplan-Meier plot of the protection from rectal HIV transmission provided by either the vehicle or topical tenofovir ([Figure 3](#pone-0060024-g003){ref-type="fig"}). Log rank analysis (p = 0.03) confirmed that topical tenofovir prevents rectal HIV-1~JRCSF~ transmission in BLT mice.

![Topical tenofovir prevents rectal HIV-1~JRCSF~ transmission in BLT mice.\
Kaplan-Meier plot indicates the time to peripheral blood conversion following rectal HIV-1~JRCSF~ exposure in BLT mice pretreated with either vehicle or topical tenofovir. Log-rank (Mantel Cox) analysis reveals a statistically significant difference in rectal HIV-1~JRCSF~ transmission between the vehicle and topical tenofovir arms.](pone.0060024.g003){#pone-0060024-g003}

Rectal Transmission of Transmitted/Founder HIV-1~THRO~ is Prevented by Topical Tenofovir {#s3c}
----------------------------------------------------------------------------------------

HIV-1~THRO~ is a CCR5-topic, MSM-derived T/F virus [@pone.0060024-Ochsenbauer1]. A total of 14 BLT mice were exposed rectally to HIV-1~THRO~ ([Figure 4](#pone-0060024-g004){ref-type="fig"}). Eight mice received vehicle and six mice received tenofovir. Five of the mice receiving vehicle were infected as determined by the presence of plasma virus RNA ([Figure 4A](#pone-0060024-g004){ref-type="fig"}). In contrast, none of the tenofovir treated BLT mice (0/6) exposed rectally to HIV-1~THRO~ exhibited plasma viremia ([Figure 4A](#pone-0060024-g004){ref-type="fig"}). In addition to plasma viremia, we also monitored the levels of human CD4^+^ T cells in the peripheral blood of all the HIV-1~THRO~ exposed mice. The levels of human CD4^+^ T cells in the infected mice did not change throughout the course of infection ([Figure 4B](#pone-0060024-g004){ref-type="fig"}).

![Analysis of peripheral blood and tissues for the presence of HIV-1~THRO~ after rectal exposure in the presence or absence of topical tenofovir.\
(A--B) Longitudinal analyses of peripheral blood plasma viral RNA (A) and the percentage of peripheral blood CD3^+^ T cells also expressing CD4 (B) are presented for vehicle (left) and topical tenofovir (right) -treated BLT mice exposed rectally to HIV-1~THRO~. (C) Real-time PCR analysis of tissues for presence or absence of HIV-1 DNA. Thin dashed lines represent the limit of detection for the respective assays. Error bars indicate standard error of the mean. Open symbols are used to depict data from HIV negative mice and closed symbols are used to depict data from HIV positive mice.](pone.0060024.g004){#pone-0060024-g004}

To confirm the lack of HIV-1 infection of the tenofovir treated mice we used real time PCR to determine the presence of cell-associated HIV-1 DNA in tissues obtained from these mice. None of the mice treated with tenofovir had detectable levels of viral DNA in any of the tissues examined ([Figure 4C](#pone-0060024-g004){ref-type="fig"}; [Table 2](#pone-0060024-t002){ref-type="table"}). In contrast, the presence of viral DNA in tissues from infected animals was readily confirmed ([Figure 4C](#pone-0060024-g004){ref-type="fig"}; [Table 2](#pone-0060024-t002){ref-type="table"}). Log rank analysis of these results presented in a Kaplan-Meier plot ([Figure 5](#pone-0060024-g005){ref-type="fig"}) revealed that topical tenofovir administered prior to exposure to BLT mice prevents rectal transmission of the physiologically relevant T/F virus, HIV-1~THRO~ (p = 0.02).

![Topical tenofovir prevents rectal transmission of HIV-1~THRO,~ a T/F virus~,~ in BLT mice.\
Kaplan-Meier plot indicates the time to peripheral blood conversion following rectal HIV-1~THRO~ exposure in BLT mice pretreated with either vehicle or topical tenofovir. Log-rank (Mantel Cox) analysis reveals a statistically significant difference in rectal HIV-1~THRO~ transmission between the vehicle and topical tenofovir arms.](pone.0060024.g005){#pone-0060024-g005}

Discussion {#s4}
==========

Mucosal infection after sexual intercourse is the most common route of HIV-1 transmission worldwide which makes the cervicovaginal and rectal mucosa the two most important anatomical sites for viral exposure [@pone.0060024-WHOUNAIDS1]. Receptive anal intercourse has the highest risk of HIV-1 infection and accounts for most new infections in the US [@pone.0060024-Boily1], [@pone.0060024-USCDC1]. Nevertheless, the vast majority of past and ongoing clinical trials for HIV prevention using topical microbicides have focused on preventing vaginal HIV-1 acquisition [@pone.0060024-Cutler1], [@pone.0060024-AbdoolKarim1], [@pone.0060024-McGowan2], [@pone.0060024-Peterson1]--[@pone.0060024-VanDamme3]. The formulation of tenofovir 1% gel used in the RMP-02/MTN-006 Phase 1 rectal safety study was the same formulation used vaginally in the CAPRISA 004 trial [@pone.0060024-AbdoolKarim1], [@pone.0060024-Anton2]. Unfortunately, there was a significant increase in gastrointestinal adverse events seen in the RMP-02/MTN-006 study, possibly due to the hyperosmolar nature of the gel [@pone.0060024-Anton2], [@pone.0060024-McGowan2]. We therefore elected to evaluate the efficacy of tenofovir directly, in the absence of any type of gel, to make a clear determination of the potential efficacy of tenofovir for the prevention of rectal HIV transmission. Our study supports the choice of tenofovir as an appropriate active pharmaceutical ingredient around which a specifically engineered microbicide can be designed for rectal [@pone.0060024-Anton1]--[@pone.0060024-McGowan2] or dual compartment use [@pone.0060024-Dezzutti1], [@pone.0060024-Dezzutti2].

Our goal was to evaluate the *in vivo* efficacy of a rectal microbicide candidate for inclusion into a rectal microbicide to prevent HIV-1 acquisition. We focused on rectal HIV transmission because this route of virus spread continues to be a major contributor to the number of men and women becoming infected with HIV [@pone.0060024-Jansen1]--[@pone.0060024-Kalichman1]. We chose a topical intervention because of the many potential benefits associated with this drug delivery route [@pone.0060024-Thigpen1], [@pone.0060024-Shattock1], [@pone.0060024-Anton2]--[@pone.0060024-Tan1]. BLT mice were chosen as the experimental platform for this evaluation because previous studies have shown that FDA approved drugs prevent mucosal HIV transmission of the human primary virus isolate HIV-1~JRCSF~ in this model [@pone.0060024-Denton3], [@pone.0060024-Denton4], [@pone.0060024-Denton5]. Here when BLT mice were pretreated with topical tenofovir (or vehicle) and then rectally exposed to HIV-1~JRCSF~, we found that topical tenofovir efficiently prevents rectal transmission of HIV-1~JRCSF~ ([Figures 2](#pone-0060024-g002){ref-type="fig"} and [3](#pone-0060024-g003){ref-type="fig"}; [Table 1](#pone-0060024-t001){ref-type="table"}).

To extend and expand on this observation we also evaluated the protective effect of tenofovir using a second virus, HIV-1~THRO~. HIV-1~THRO~ is a MSM-derived T/F virus and therefore its evaluation in the context of rectal transmission is of significant relevance [@pone.0060024-Ochsenbauer1]. T/F viruses represent the one or few founder viruses that undergo amplification in local T cells and subsequent systemic dissemination after mucosal exposure [@pone.0060024-Ochsenbauer1]--[@pone.0060024-SalazarGonzalez1], [@pone.0060024-Haase1]. These T/F viruses use CCR5 as a coreceptor for entry and replicate poorly in monocyte/macrophages relative to T cells [@pone.0060024-Ochsenbauer1]. Despite their intrinsic relevance, T/F viruses have not been previously used for *in vivo* transmission studies in animal models. We found that HIV-1~THRO~ transmits rectally in BLT mice and that its transmission can be efficiently prevented by pretreatment with rectally applied tenofovir ([Figures 4](#pone-0060024-g004){ref-type="fig"} and [5](#pone-0060024-g005){ref-type="fig"}; [Table 2](#pone-0060024-t002){ref-type="table"}).

Analysis of the data from two HIV-1 isolates indicates that 1 of 18 BLT mice became infected despite treatment with topical 1% tenofovir prior to rectal HIV-1 exposure, while 13 of 25 vehicle treated BLT mice became infected (p = 0.002 Fisher's exact test) ([Tables 1](#pone-0060024-t001){ref-type="table"} and [2](#pone-0060024-t002){ref-type="table"}). In an *in vivo* study using non-human primates (NHP), 2 of 6 macaques became infected despite treatment with topical 1% tenofovir 15 minutes prior to rectal SIV exposure, while 3 of 4 vehicle treated macaques became infected [@pone.0060024-Cranage1]. The conclusion reached by the authors of the macaque study and our conclusion of the study presented here are the same -- topical tenofovir can inhibit rectal transmission of SIV [@pone.0060024-Cranage1], primary HIV-1 ([Figure 3](#pone-0060024-g003){ref-type="fig"}) and T/F HIV-1 ([Figure 5](#pone-0060024-g005){ref-type="fig"}).

Topical microbicides are of significant interest in HIV prevention because they achieve high local drug concentrations capable of preventing HIV transmission with reduced risk for toxicity [@pone.0060024-Thigpen1], [@pone.0060024-Shattock1], [@pone.0060024-Anton2]. The *in vivo* preclinical efficacy data presented here together with previous data from NHP [@pone.0060024-Cranage1] show that topical tenofovir can efficiently block rectal transmission. The incorporation of a physiologically relevant T/F HIV-1 into this study of rectal HIV prevention increases its translational value. The results presented here show the importance of animal models for the evaluation of HIV-1 prevention strategies and demonstrate the potential for efficacy of tenofovir-based rectal microbicides in humans. Future studies will leverage the results from this work and the BLT model to perform dose-ranging tenofovir studies, evaluate rectal-specific gel formulations containing tenofovir and evaluate other topical rectal microbicide agents for efficacy.
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